CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group

Norbert Schmitz(University Hospital Münster), Michael Pfreundschuh(Saarland University), Markus Loeffler(Leipzig University), Lorenz Truemper(University of Göttingen), B. Glaß(University of Göttingen), Eva Cavallin‐Ståhl(Lund University), Ulrich Kaiser(University of Applied Sciences Landshut), M Wolf(Peter MacCallum Cancer Centre), Samira Zeynalova(Leipzig University), Mathias Haenel(Klinikum Chemnitz)
Annals of Oncology
October 12, 2011
10.1093/annonc/mdr440
Cited by 105

Related Papers

Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes
|Nature Communications|2018|1k
A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling
|New England Journal of Medicine|2006|1k